

Special Issue

Gram-Positive Cocci: Antimicrobial Resistance, Treatment, Susceptibility, and New Therapeutic Options

Message from the Guest Editor

Gram-positive cocci, including *Staphylococcus*, *Streptococcus*, and *Enterococcus* species, are among the most clinically significant pathogens worldwide. Their ability to cause a wide range of infections makes them a persistent challenge in both hospital and community settings. The increasing prevalence of antimicrobial resistance, including methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant enterococci, macrolide-resistant *Streptococcus pneumoniae*, macrolide-resistant *Streptococcus pyogenes*, and penicillin-resistant *Streptococcus agalactiae*, has further complicated treatment and infection control strategies, placing them on the 2024 WHO Bacterial Priority Pathogens List, which urgently requires new therapeutic options. This Special Issue aims to explore recent advances in understanding resistance mechanisms, current trends in susceptibility and treatment, and the clinical implications of drug-resistant Gram-positive cocci. We also welcome original research, reviews, and short communications on novel antimicrobial agents, therapeutic strategies, diagnostic tools, and alternative approaches such as phage therapy, CRISPR-Cas, nanotechnology, and antimicrobial peptides.

Guest Editor

Prof. Dr. Felipe Piedade Gonçalves Neves
Instituto Biomédico, Universidade Federal Fluminense, Niterói, Brazil

Deadline for manuscript submissions

30 July 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/250410

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)